RemeGen (HKG:9995) sold the license to its RC148 medicine to AbbVie, under a deal with an upfront payment of $650 million, according to a Hong Kong bourse filing Monday.
Shares of the biopharmaceutical research company gained over 9% in morning trade Tuesday.
The license covers all regions outside Greater China, and RemeGen is eligible to receive up to a further $4.95 billion in milestone payments. The firm will also receive royalties on the sales of the drug once it is commercialized.
RC148 is being developed as an anti-tumor medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments